Literature DB >> 28151715

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials-Response.

Paul G Kluetz1, Elektra J Papadopoulos2, Laura Lee Johnson3, Martha Donoghue4, Virginia E Kwitkowski4, Wen-Hung Chen2, Rajeshwari Sridhara3, Ann T Farrell4, Patricia Keegan4, Geoffrey Kim4, Richard Pazdur4.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 28151715      PMCID： PMC5895452          DOI： 10.1158/1078-0432.CCR-16-2140

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  1 in total

1.  Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms.

Authors:  Paul G Kluetz; Ashley Slagle; Elektra J Papadopoulos; Laura Lee Johnson; Martha Donoghue; Virginia E Kwitkowski; Wen-Hung Chen; Rajeshwari Sridhara; Ann T Farrell; Patricia Keegan; Geoffrey Kim; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2016-01-12       Impact factor: 12.531
  1 in total
  10 in total

1.  Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.

Authors:  Amylou C Dueck; Howard I Scher; Antonia V Bennett; Gina L Mazza; Gita Thanarajasingam; Gisela Schwab; Aaron L Weitzman; Lauren J Rogak; Ethan Basch
Journal:  JAMA Oncol       Date:  2020-02-13       Impact factor: 31.777

2.  Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Arlene E Chung; Kimberly Shoenbill; Sandra A Mitchell; Amylou C Dueck; Deborah Schrag; Deborah W Bruner; Lori M Minasian; Diane St Germain; Ann M O'Mara; Paul Baumgartner; Lauren J Rogak; Amy P Abernethy; Ashley C Griffin; Ethan M Basch
Journal:  J Am Med Inform Assoc       Date:  2019-04-01       Impact factor: 4.497

Review 3.  Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers.

Authors:  Risa L Wong; Alicia K Morgans
Journal:  Curr Oncol Rep       Date:  2020-02-08       Impact factor: 5.075

4.  Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.

Authors:  Bradley McGregor; Peter H O'Donnell; Arjun Balar; Daniel Petrylak; Jonathan Rosenberg; Evan Y Yu; David I Quinn; Elisabeth I Heath; Mary Campbell; Zsolt Hepp; Caroline McKay; Joyce Steinberg; Antoine Regnault; Flora Mazerolle; Matthew D Galsky
Journal:  Eur Urol       Date:  2022-02-12       Impact factor: 24.267

5.  Patient-Reported Outcomes for Tolerability Assessment in Phase I Cancer Clinical Trials.

Authors:  Ethan Basch; Christina Yap
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506

6.  Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Ethan Basch; Claus Becker; Lauren J Rogak; Deborah Schrag; Bryce B Reeve; Patricia Spears; Mary Lou Smith; Mrinal M Gounder; Michelle R Mahoney; Gary K Schwartz; Antonia V Bennett; Tito R Mendoza; Charles S Cleeland; Jeff A Sloan; Deborah Watkins Bruner; Gisela Schwab; Thomas M Atkinson; Gita Thanarajasingam; Monica M Bertagnolli; Amylou C Dueck
Journal:  Clin Trials       Date:  2020-12-01       Impact factor: 2.486

Review 7.  A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer.

Authors:  Michelle K Wilson; Rebecca Mercieca-Bebber; Michael Friedlander
Journal:  J Gynecol Oncol       Date:  2018-06-09       Impact factor: 4.401

8.  Patient-Reported Outcomes in Pediatric Cancer Registration Trials: A US Food and Drug Administration Perspective.

Authors:  Meena N Murugappan; Bellinda L King-Kallimanis; Gregory H Reaman; Vishal Bhatnagar; Erica G Horodniceanu; Najat Bouchkouj; Paul G Kluetz
Journal:  J Natl Cancer Inst       Date:  2022-01-11       Impact factor: 13.506

9.  Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30.

Authors:  Antoine Regnault; Farrah Pompilus; Anna Ciesluk; Flora Mazerolle; Rafael Bejar; Robert J Fram; Douglas V Faller; Patrick Marquis; Jill A Bell
Journal:  J Patient Rep Outcomes       Date:  2021-07-20

Review 10.  Measuring Quality of Life in Ovarian Cancer Clinical Trials-Can We Improve Objectivity and Cross Trial Comparisons?

Authors:  Gita Bhat; Katherine Karakasis; Amit M Oza
Journal:  Cancers (Basel)       Date:  2020-11-07       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.